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• All other authors have no conflicts to report 11 12 13 1 overall survival (OS) was 88%, cancer-specific survival (CSS) 92%, primary tumor 2 control (TC) 94%, and freedom from recurrence (FFR) 67%. In patients with KRAS-3 mutant tumors, there was a significantly lower TC (67% vs. 96%; p=0.04), FFR (48% vs. 4 69%; p=0.03), and CSS (75% vs. 93%; p=0.05). On multivariable analysis, histology 5 was not associated with outcomes, but KRAS mutation (HR: 10.3, 95% CI: 2.3-45.6; 6 p=0.0022) was associated with decreased CSS after adjusting for age. 7 8 CONCLUSION:
9
In this SBRT series, histology was not associated with outcomes, but KRAS mutation 10 was associated with lower FFR on univariable analysis, and decreased CSS on 11 multivariable analysis. Due to small sample size, these hypothesis-generating results 1 Stereotactic body radiation therapy (SBRT) has emerged as the treatment of 2 choice for medically inoperable stage I non-small cell lung cancer (NSCLC) in the past 3 decade. Multiple prospective 1-3 and retrospective 4-6 series of different SBRT regimens 4 have demonstrated very high local control (80-90% at 2-3 years), high overall survival 5 (50-60%) and cancer-specific survival rates (60-70%) compared to historical series of 6 patients treated with conventionally fractionated radiation therapy (RT). However, in 7 these series, both regional and distant recurrences remain an issue with reported 8 incidences of 5-13% and 14-25%, respectively. 1, 2, 4, 6 Thus, developing prognostic 9 markers that identify patients at highest risk for recurrence after SBRT remains an 10 important area for further research.
12
Alongside the emergence of SBRT technology, advances in cancer genomics in 13 the last decade have identified genetically distinct sub-groups of lung adenocarcinoma 14 defined by mutations in oncogenes such as v-Ki-ras2 Kirsten rat sarcoma viral oncogene 15 homolog (KRAS) and epidermal growth factor receptor (EGFR). 7 The unique biology of 16 each genotypic sub-group has led to the development of personalized, "genotype-17 directed" therapy in the stage IV setting resulting in the widespread adoption of clinical 18 EGFR mutation testing and evidence that first line EGFR tyrosine kinase inhibitor 19 therapy results in improved outcomes. 8-10 20 21 However, the role of tumor genotype in earlier stages of disease remains under-22 studied and controversial. KRAS mutation status has been studied extensively as both a 23 prognostic factor and predictor of response to chemotherapy in stage I NSCLC patients 24 with conflicting, inconclusive results. 11-17 Furthermore, the radiation responsiveness and 25 clinical outcomes after RT for the genotypic subgroups of NSCLC have not been well 26 6 elucidated. Prior studies have shown possible associations between NSCLC genotype 1 and response to RT. For example, retrospective series have demonstrated that patients 2 with locally advanced EGFR mutant NSCLC had lower risk of locoregional failure 3 compared to EGFR-wild-type patients after chemotherapy and conventional RT, [18] [19] [20] 4 while patients with KRAS-mutant LA-NSCLC had decreased overall survival compared 5 to those with KRAS-wild-type tumors. 19 However, it remains unclear if differences in 6 radiation response by genotype is relevant at the higher doses delivered with SBRT.
8
Since patients receiving SBRT for stage I NSCLC typically have substantial 9 medical co-morbidities that often preclude adjuvant chemotherapy, this patient subset 10 provides a unique population to study KRAS-genotype as a potential prognostic marker.
11
In this retrospective study, we build on these prior studies by performing an analysis of Deleted: comparing pathology department or in a commercial laboratory. Briefly, in all cases, DNA was 1 isolated from tumor in paraffin-embedded tissue specimens and polymerase chain 2 reaction using primers specific for codon 12, 13 and 61 of the KRAS gene was 3 performed. 21 The primer extension products were then analyzed by capillary gel 4 electrophoresis. Only one patient's tumor sample underwent testing for EGFR mutation 5 status and none were tested for ALK mutation status. Thus, these tumor characteristics 6 were not assessed.
8
Covariates:
9 Pre-treatment patient characteristics were collected, including age, gender, race, 
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All patients were treated with SBRT per institutional norms, which included 1) 20 restriction of SBRT to peripheral tumors as defined in RTOG 0236; 2 2) use of abdominal 21 compression to restrict tumor motion < 1 cm; 3) 4D-CT planning to create an internal 22 target volume (ITV); 4) a 5 mm planning target volume (PTV) margin with no clinical 23 target volume (CTV) margin; 5) dose of 10-12 Gy x 5 fractions for tumors close to the 24 chest wall and 18 Gy x 3 fractions for all other tumors; 6) daily setup and image-guided 25 8 treatment with Exac Trac®, cone-beam CT, and portal imaging using a linear 1 accelerator.
2
Patients were followed every 3-4 months after treatment for the first two years 3 with a chest CT, then every 6 months for the next three years, and annually thereafter. Overall survival (OS), cancer-specific survival (CSS) and patterns of failure, 7 including local tumor control (TC; absence of tumor recurrence in-field or within 1 cm of 8 PTV), lobar control (LC; including local tumor control and absence of recurrence in the 9 same lobe), regional control (RC; absence of hilar and mediastinal recurrences), local-10 regional control (LRC; composite endpoint of lobar and regional control), freedom from 11 distant metastases (FFDM), freedom from any recurrence (FFR), and recurrence-free 
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There was also no significant difference in patterns of recurrence when 23 comparing by adenocarcinoma (n=35) primary TC (HR: 8.0; 95% CI: 0.82-78.4; p=0.07). On multivariable analysis with 1 backward selection, no variables were associated with any of these local and/or regional 2 recurrence endpoints. Neither univariable nor multivariable analysis with backward 3 selection identified any clinical variables associated with risk of distant recurrence.
5
However, univariable analysis of any recurrence demonstrated that KRAS 6 mutation status was associated with increased incidence of any recurrence (HR: 3.2; 7 95% CI 1.1-9.6; p=0.04; Table 4 ). However, no variables were associated with FFR on 8 multivariable analysis with backward selection.
10
On univariable and multivariable analysis of CSS with death of other causes as a 11 competing risk, presence of KRAS mutation was associated with increased risk of death 12 from lung cancer (HR: 10.3, 95% CI: 2.3-45.6; p=0.0022), after adjusting for age (Table   13 5; Figure 1 ).
15
DISCUSSION:
16
In this study of patients treated with SBRT for early stage NSCLC, we 17 demonstrate high primary TC and OS with the predominant sites of failure in regional 18 nodes or distant sites, which is comparable to previously published series. 1, 2, 6 We 19 performed sub-group analyses to determine whether tumor biology as reflected by tumor 20 histology or genotype was associated with outcomes after SBRT. We demonstrated that 21 tumor histology was not associated with local, regional or distant recurrence, but KRAS 22 mutation status was associated with decreased TC and FFR on univariable analysis, 23 and decreased CSS on multivariable analysis. 24 25 1 histology and increased risk of distant metastases, 2 but few have studied association 2 between NSCLC histology and TC. In our series, there was not a clear association 3 between TC and histology, but of note, primary tumor recurrences occurred in only 4 patients with adenocarcinoma histology. The high biologically equivalent dose delivered 5 with SBRT and low incidence of local failure events likely minimizes the likelihood of 6 detecting a histological difference in radiosensitivity, particularly in small series. Further 7 study of TC by tumor histology will likely require pooled analyses of larger SBRT 8 datasets.
10
The most interesting finding of this study was an association between KRAS 11 mutation status with FFR and CSS. The role of KRAS mutation status as a potential 12 prognostic and predictive marker for early stage NSCLC remains controversial. A recent 13 pooled analysis of multiple adjuvant chemotherapy trials demonstrated that KRAS 14 mutation status was not prognostic, but codon 13 KRAS mutation was possibly 15 predictive of decreased response to chemotherapy (HR = 5.78; 95% CI, 2.06 to 16.2; 16 P<0.001; interaction P =0.002). 15 In our study, there was no clear association between 17 primary TC and KRAS mutations status, but the high dose delivered with SBRT may 18 obscure any underlying variability in radiation responsiveness that may be imparted by 19 tumor genotype, and the low number of primary tumor recurrence events with SBRT also 20 reduces the power to detect any such association. However, our study demonstrated an 21 association between KRAS mutation status and both CSS and risk of any recurrence.
22
However, given the small sample size, this hypothesis generating results must be further 23 studied in a larger dataset before KRAS genotype can be utilized as a prognostic 24 biomarker among patients treated with SBRT. Since our study and other published 25 SBRT series demonstrate that distant metastases and regional nodes are the predominant sites of failure, 1-3, 6 potential biomarkers such as KRAS mutation status that 1 identify patients at high risk for such recurrence may help guide the use of adjuvant 2 therapy, and may be particularly important in the medically ill subset of patients treated 3 with SBRT.
5
One of the main limitations of this study was incomplete genotyping. There is a 6 possibility that incomplete genotyping may introduce bias, but since KRAS mutations are 7 present in approximately 20% of adenocarcinomas, it is likely that the incomplete 8 genotyping would bias the results toward the null, since there would be patients with 9 undetected KRAS in the control group. Another unusual finding was the high incidence 10 of KRAS mutations (70%; n=7) in the subset of patients (n=10) who had tumor 11 genotyping, which may have been due to chance or possibly due to the heavy smoking 12 history in this patient population (>95% were smokers with median 50 pack-years 13 history). Thus, the association between outcomes and KRAS mutation status must be 14 interpreted with caution due the potential for confounding given the unexpectedly high 15 incidence of KRAS mutation in the genotyped cohort, and the association between 16 KRAS mutation and larger tumor size in this study.
18
Additionally, less common genotypic subgroups such as patients with EGFR-19 mutant or ALK-translocated tumors could not be analyzed in this cohort due to small 20 numbers and lack of testing, which was not clinically-indicated due to the low incidence 21 of alterations of these genes in a group of patients with heavy smoking . Similarly, this 22 study was conducted in an era where clinical genotyping involved only a limited panel of 23 genes (KRAS, EGFR, and ALK), and thus, co-mutations in genes that are known to alter 24 the underlying biology of KRAS mutant tumors such as LKB1 and p53 were not 25 genotyped. 22 Clearly, further studies analyzing outcomes after SBRT by genotyping 26 Ray 9/20/14 3:44 PM Ray 9/20/14 3:48 PM Deleted: Regardless, these findings must be validated in a larger dataset.
Deleted: tumor responsiveness to 1 limited by the difficulty of obtaining sufficient tumor samples in the medically inoperable 2 subset of patients with NSCLC. For instance, in this study, the majority of patients 3 underwent fine-needle aspiration which precluded additional genetic analyses.
4
Additionally, due to concerns for significant potential biopsy-related morbidity (e.g. 
